Production (Stage)
Citius Pharmaceuticals, Inc.
CTXR
$0.703
-$0.021-2.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.76% | 9.47% | -2.05% | -23.75% | 7.44% |
| Total Depreciation and Amortization | 2.19% | 2.05% | 1.70% | 1.34% | 2.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.18% | -8.89% | -24.65% | -0.14% | 1.29% |
| Change in Net Operating Assets | 45.66% | 16.60% | 300.03% | 55.53% | -1,019.66% |
| Cash from Operations | 3.94% | 20.07% | 29.34% | -7.47% | -26.90% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 34.64% | 2,939.08% | -99.38% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 34.64% | 168.70% | -127.31% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 50.10% | 85.32% | -373.92% | 168.73% | -26.90% |